Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : Tseng Lab on the move? -- Ignore unavailable to you. Want to Upgrade?

To: muddphudd who wrote (222)	10/26/1998 3:48:00 PM
From: Urlman	Respond to of 251

REAL AUDIO PROGRAM WITH CELL PATHWAY Hosted by Lou Cattaruzza http://www.audionet.com/business/events/wcn/cell_sys.ram WCNradio â€“ Cell Pathwaysâ€™ President and CEO Bob Towarnicki elaborates on the companyâ€™s May 20 report on the success of its Phase II extension study of FGN-1 in the treatment of Familial Adenomatous Polyposis, a genetic disorder resulting in colon cancer. Significantly, the drug provides a novel, highly selective means for inducing programmed cell death, or apotosis, in precancerous and cancerous lesions, which leaves healthy cells unharmed. The company is also conducting studies on the use of FGN-1 in the treatment of prostate, lung and breast cancer. Although the company postponed a scheduled IPO due to market conditions for biotech companies, Towarnicki is pleased with the companyâ€™s successful $18 million private financing. ====== If you are a fan of Real Audio please visit my website killpopradio.com